SANOFI-AVENTIS (EPA:SAN) Press Release: FDA approves once-weekly ALTUVIIIO™, a new class of factor VIII therapy for hemophilia A that offers significant bleed protection
Directive transparence : information réglementée
23/02/2023 22:00
01/06/2023 07:30
01/06/2023 07:30
21/05/2023 20:17
21/05/2023 20:17
17/05/2023 22:01
17/05/2023 22:01
12/05/2023 10:50
04/05/2023 08:00
04/05/2023 08:00
27/04/2023 14:40